Myasthenia gravis trials in Spain

In Spain 21 Also abroad 123

21 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients with Myasthenia Gravis
Where
Barcelona
Age
18 years and over
People
59 worldwide
Run by
NMD Pharma A/S
See details and how to join2023-507539-40-00 · EU 2023-507539-40-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Alicante, Barcelona, Bilbao, L'hospitalet De Llobregat, Madrid, Málaga, Murcia, San Sebastián de los Reyes, Sevilla
Age
18 years and over
People
120 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00
Phase 3Taking people
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Alicante, Barcelona, Bilbao, L'hospitalet De Llobregat, Madrid, Málaga, Murcia, San Sebastián de los Reyes, Sevilla
Age
18 years and over
People
100 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00
Phase 3Taking people
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Where
Alicante, Barcelona, Bilbao, Sevilla, Valencia
Age
18 years and over
People
199 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00
No phaseTaking people
Holistic Assessment and Remote Digital MONitoring of mYasthenia Gravis Via MyoSense 360
Where
Barcelona, Madrid, Santiago de Compostela
Age
18 years and over
People
100 worldwide
Run by
Ad scientiam
See details and how to joinNCT07323316
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Barcelona, Málaga
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
Phase 2/3Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Where
Esplugues De Llobregat, Valencia
Age
2 years to 18 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00
Phase 3Taking people
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Where
Barcelona, Donostia, Madrid, San Sebastián de los Reyes, Sevilla, Valencia
Age
18 years to 74 years
People
115 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07217587 · EU 2025-521130-28-00
Phase 3Taking people
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Where
Barcelona, Madrid
Age
18 years to 80 years
People
195 worldwide
Run by
Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00
No phaseTaking people
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Where
Barcelona, Málaga
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07294170
Phase 2Taking people
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Where
Esplugues de Llobregat, Valencia
Age
2 years to 17 years
People
15 worldwide
Run by
Amgen
See details and how to joinNCT06987539 · EU 2025-520993-20-00
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Badalona, Barcelona, Córdoba, Oviedo, Valencia
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 1/2Taking people
A Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of Aritinercept, a Dual BAFF/APRIL Inhibitor, in Patients with Generalized Myasthenia Gravis
Where
Alicante, Barcelona, Donostia, Madrid, Málaga, San Sebastián de los Reyes, Sevilla, Valencia
Age
18 years and over
People
38 worldwide
Run by
Aurinia Pharmaceuticals Inc.
See details and how to join2025-525127-27-00 · EU 2025-525127-27-00
Phase 2/3Taking people
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Where
Valencia
Age
2 years to 17 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Barcelona, Málaga
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Where
Barcelona
Age
18 years and over
People
84 worldwide
Run by
NMD Pharma A/S
See details and how to joinNCT06414954
Phase 3Taking people
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Where
Barcelona, Córdoba, Madrid, Sant Cugat del Vallès
Age
18 years to 80 years
People
231 worldwide
Run by
Immunovant Sciences GmbH
See details and how to joinNCT07039916 · EU 2024-515979-35-00
No phaseTaking people
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Where
Barcelona, Madrid, Seville
Age
18 years and over
People
680 worldwide
Run by
argenx
See details and how to joinNCT06298565
No phaseTaking people
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
Where
Barcelona
People
279 worldwide
Run by
argenx
See details and how to joinNCT06299748
Phase 1/2Taking people
A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Where
Madrid, Oviedo, Pamplona
Age
18 years to 74 years
People
96 worldwide
Run by
ImmunAbs Inc.
See details and how to joinNCT07250750 · EU 2025-522406-20-00
Phase 4Taking people
Efficacy and tolerability of efgartigimod as early treatment in patients with generalized myasthenia gravis.
Where
L'hospitalet De Llobregat
Age
18 years and over
People
20
Run by
Bellvitge University Hospital
See details and how to join2024-516015-24-00 · EU 2024-516015-24-00